Percutaneous intraductal radiofrequency ablation is a safe treatment for malignant biliary obstruction: Feasibility and early results
| Autor: | Vlastimil Válek, Cristina Mosconi, Charis Kyriakides, Nagy A. Habib, Andrasina Tomas, Ao Guokun, Robert Julian Dickinson, Pietro Quaretti, Madhava Pai, Joanna Nicholls, Feng Xi, Malkhaz Mizandari, Rita Golfieri |
|---|---|
| Přispěvatelé: | Mizandari, Malkhaz, Pai, Madhava, Xi, Feng, Valek, Vlastimil, Tomas, Andrasina, Quaretti, Pietro, Golfieri, Rita, Mosconi, Cristina, Guokun, Ao, Kyriakides, Chari, Dickinson, Robert, Nicholls, Joanna, Habib, Nagy |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
Radiology Nuclear Medicine and Imaging Percutaneous Stenting Radiofrequency ablation medicine.medical_treatment law.invention Hepatic law Retrospective Studie Stent Cancer Cholestasis Bile duct Biliary Recanalization Middle Aged Ablation Survival Rate medicine.anatomical_structure Treatment Outcome Biliary tract Cholestasi Bile Duct Perforation Catheter Ablation Drainage Stents Female Radiology Cardiology and Cardiovascular Medicine Cholangiography Human Adult medicine.medical_specialty medicine Humans Bile Duct Neoplasm Retrospective Studies Aged business.industry medicine.disease Feasibility Studie Bile Duct Neoplasms Pancreatitis Feasibility Studies business Tomography X-Ray Computed |
| Popis: | Purpose: Previous clinical studies have shown the safety and efficacy of this novel radiofrequency ablation catheter when used for endoscopic palliative procedures. We report a retrospective study with the results of first in man percutaneous intraductal radiofrequency ablation in patients with malignant biliary obstruction. Methods: Thirty-nine patients with inoperable malignant biliary obstruction were included. These patients underwent intraductal biliary radiofrequency ablation of their malignant biliary strictures following external biliary decompression with an internal-external biliary drainage. Following ablation, they had a metal stent inserted. Results: Following this intervention, there were no 30-day mortality, hemorrhage, bile duct perforation, bile leak, or pancreatitis. Of the 39 patients, 28 are alive and 10 patients are dead with a median survival of 89.5 (range 14-260) days and median stent patency of 84.5 (range 14-260) days. One patient was lost to follow-up. All but one patient had their stent patent at the time of last follow-up or death. One patient with stent blockage at 42 days postprocedure underwent percutaneous transhepatic drain insertion and restenting. Among the patients who are alive (n = 28) the median stent patency was 92 (range 14-260) days, whereas the patients who died (n = 10) had a median stent patency of 62.5 (range 38-210) days. Conclusions: In this group of patients, it appears that this new approach is feasible and safe. Efficacy remains to be proven in future, randomized, prospective studies. © 2012 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|